Abstract
The identification of autophosphorylation of the insulin receptor as a pivotal component in the signal transduction induced by insulin, initiated the hunt to identify the tyrosine phosphatase(s) that were responsible for regulating dephosphorylation, and thus inactivation of the receptor. Compelling evidence for the existence of an insulin receptor specific PTP has come from the remarkable phenotype of the PTP1B deficient mouse. PTP1B deficient mice display an insulin sensitive phenotype and are able to maintain glucose homeostasis with about half the level of circulating insulin. In response to insulin administration PTP1B deficient mice have a significant increase in insulin receptor phosphorylation in liver and muscle compared to wild type controls. Unexpectedly these animals were also resistant to diet induced obesity. These observations strongly support PTP1B as a negative regulator of insulin action, thereby making it an ideal therapeutic target for intervention in type 2 diabetes and obesity.
Keywords: Protein Tyrosine Phosphatase, Diabetes and Obesity, autophosphorylation, tyrosine phosphatase, phenotype
Current Topics in Medicinal Chemistry
Title: Protein Tyrosine Phosphatase 1B: A Novel Target for Type 2 Diabetes and Obesity
Volume: 3 Issue: 7
Author(s): Chidambaram Ramachandran and Brian P. Kennedy
Affiliation:
Keywords: Protein Tyrosine Phosphatase, Diabetes and Obesity, autophosphorylation, tyrosine phosphatase, phenotype
Abstract: The identification of autophosphorylation of the insulin receptor as a pivotal component in the signal transduction induced by insulin, initiated the hunt to identify the tyrosine phosphatase(s) that were responsible for regulating dephosphorylation, and thus inactivation of the receptor. Compelling evidence for the existence of an insulin receptor specific PTP has come from the remarkable phenotype of the PTP1B deficient mouse. PTP1B deficient mice display an insulin sensitive phenotype and are able to maintain glucose homeostasis with about half the level of circulating insulin. In response to insulin administration PTP1B deficient mice have a significant increase in insulin receptor phosphorylation in liver and muscle compared to wild type controls. Unexpectedly these animals were also resistant to diet induced obesity. These observations strongly support PTP1B as a negative regulator of insulin action, thereby making it an ideal therapeutic target for intervention in type 2 diabetes and obesity.
Export Options
About this article
Cite this article as:
Ramachandran Chidambaram and Kennedy P. Brian, Protein Tyrosine Phosphatase 1B: A Novel Target for Type 2 Diabetes and Obesity, Current Topics in Medicinal Chemistry 2003; 3 (7) . https://dx.doi.org/10.2174/1568026033452276
DOI https://dx.doi.org/10.2174/1568026033452276 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents on Biomedical Applications for the Treatment of Atherosclerosis
Recent Patents on Regenerative Medicine Development and Characterization of Novel Medicated Nanofibers Against Periodontitis
Current Drug Delivery Selective Estrogen Receptor Modulators. Current and Future Treatment Options for Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research Neurobiology of Depression and Novel Antidepressant Drug Targets
Current Pharmaceutical Design Advances in High-Field Magnetic Resonance Spectroscopy in Alzheimer’s Disease
Current Alzheimer Research Effect of Aqueous Extract of Azadirachta indica Leaves on Pharmacokineics and Pharmacodynamics of Glipizide
Drug Metabolism Letters Design and Development of Oral Nanoparticulated Insulin in Multiple Emulsion
Current Drug Delivery Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design In vitro characterisation of Span™ 65 niosomal formulations containing proteins
Current Drug Delivery Pharmacological Neuroprotection after Perinatal Hypoxic-Ischemic Brain Injury
Current Neuropharmacology Efficient Synthesis of Five and Six Member Sultam
Letters in Organic Chemistry α<sub>IIb</sub>β<sub>3</sub>-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells
Current Drug Targets Surfactant Protein (SP)-A and SP-D as Antimicrobial and Immunotherapeutic Agents
Recent Patents on Anti-Infective Drug Discovery The Role and Potential Therapeutical Applications of Antimicrobial Proteins in Infectious and Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Current Pharmaceutical Design The Nervous System as a Critical Regulator of Immune Responses Underlying Allergy
Current Pharmaceutical Design Editorial: Lipoprotein (a), More than Just Cholesterol?
Current Medicinal Chemistry Thyroid Peroxidase Antibody (TPO) as a Predictor of Radiation Induced Thyroid Dysfunction Among Nurses and Technicians Working in Mansoura Specialized Medical Hospital: Cross Sectional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Financial Returns on R&D: Looking Back at History, Looking Forward to Adaptive Licensing
Reviews on Recent Clinical Trials